Efficacy of dupilumab in real-life settings: a STROBE study
European Archives of Oto-Rhino-Laryngology · 2024
DOI: 10.1007/s00405-024-08553-9 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2024. Verfasst von A Gal und 5 weiteren Autor:innen. Beteiligte Einrichtung: APHM, La Conception University Hospital, ENT-HNS, Department, Aix Marseille Univ, Marseille, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Sinusitis, Rhinitis, Quality of Life. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Dupilumab, a monoclonal antibody targeting IL-4 and IL-13, has demonstrated its efficacy in several clinical trials. However, to date, real-life data remains limited. OBJECTIVE: The aim of our study was to assess the real-life impact of dupilumab on patients with severe and uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) quality of life. MATERIALS AND METHODS: This was a retrospective, monocentric, observational, real-life study, conducted in accordance with the STROBE guidelines. The following parameters were collected before treatment and at 1, 4, and 12 months: Sino-Nasal Outcome Test-22 (SNOT-22), nasal polyp score (NPS), Sniffin' Sticks-16 (SST-16), visual analog scale (VAS) for loss of smell, nasal congestion score (NCS), gustatory VAS, asthma control, oral corticosteroid usage, surgery rates, and occurrence of side effects. RESULTS: The study included 47 patients. SNOT-22 scores decreased from 52.4 ± 24.3 to 12.7 ± 10.5 at 12 months (p < 0.001). NPS decreased from 6.15 ± 1.71 to 1.57 ± 1.40 at 12 months (p < 0.001). SST-16 scores increased from 1.6 ± 2.83 to 9.1 ± 5.4 at 12 months (p < 0.001). NCS decreased from 2.45 ± 0.72 to 0.38 ± 0.63 at 12 months (p < 0.001). Prior to treatment, 72.3% were using oral corticosteroids, compared to 17.0% at 12 months (p < 0.01). Two patients required additional surgery, and 17% reported completely uncontrolled asthma, compared to 0% at 12 months (p < 0.01). CONCLUSION: Our real-life results confirm the efficacy of Dupilumab in the treatment of severe and uncontrolled CRSwNP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- APHM, La Conception University Hospital, ENT-HNS, Department, Aix Marseille Univ, Marseille, France.
- APHM, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Hop Timone, BioSTIC, Biostatistique et Technologies de l'Information et de La Communication, Aix Ma…
- Aix Marseille Univ, APHM, CNRS, IUSTI, La Conception University Hospital, ENT-HNS, Department, Marseille, France, Aix Marseille Univ, Marseille, France. thomas.radulesco@ap-hm.fr.
- Aix Marseille Univ, APHM, CNRS, IUSTI, La Conception University Hospital, ENT-HNS, Department, Marseille, France, Aix Marseille Univ, Marseille, France.
Zitieren
APA
Gal, A., Gravier-Dumonceau, R., Penicaud, M., Ebode, D., Radulesco, T., & Michel, J. (2024). Efficacy of dupilumab in real-life settings: a STROBE study. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-024-08553-9
Vancouver
Gal A, Gravier-Dumonceau R, Penicaud M, Ebode D, Radulesco T, Michel J. Efficacy of dupilumab in real-life settings: a STROBE study. European Archives of Oto-Rhino-Laryngology. 2024. doi:10.1007/s00405-024-08553-9
BibTeX
@article{Gal2024,
author = {Gal, A and Gravier-Dumonceau, R and Penicaud, M and Ebode, D and Radulesco, T and Michel, J},
title = {Efficacy of dupilumab in real-life settings: a STROBE study},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2024},
doi = {10.1007/s00405-024-08553-9}
}
EUVIMED